Jiangsu Recbio Technology Co., Ltd. announce that the Group has recently completed the first batch of subject enrollment for the international multi-center phase III clinical trial of recombinant COVID-19 vaccine ReCOV. This phase III clinical trial is an international multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ReCOV as primary vaccination in adults aged 18 years and above. ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant, protein engineering and immunological evaluation platforms, and the adjuvant used therein is the self-developed novel adjuvant BFA03.

It has a variety of comprehensive advantages, including favourable neutralizing effect and immune persistence, overall positive safety profile, potential growth in production scale, low production cost, preparation stability, and ability to be stored and transported at room temperature. Based on the multiple phase II studies conducted by the Company, ReCOV has demonstrated good safety profile and excellent immune response and is able to provide definite cross-protection from the Omicron variants, outperforming the international mainstream vaccines reported to date. The Company has completed the construction of ReCOV manufacturing facility and preparation for commercial production, and has obtained the relevant vaccine production license issued by the regulatory authorities in China, which is fully prepared for commercialization in China.